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We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from
HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based
design. Our structural biology investigations reveal two notable observations. First, 2 and related com-
pounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has
not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center
of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications
of these observations are discussed, and the work described here defines key features for potent and
selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.
Introduction
Nek2 is a serine/threonine kinase that plays a key role in cell
division. It localizes to the centrosome and regulates spindle
pole organization and separation through phosphorylation of
substrates including C-Nap1, rootletin, and Nlp.a,1-5 In
addition to its centrosomal role, Nek2 has also been impli-
cated in chromatin condensation through phosphorylation of
HMGA2 and spindle checkpoint control through interaction
with or phosphorylation of Hec1, Mad1, and Mad2.6,7 Nek2
expression and activity are tightly regulated in a cell cycle-
dependent manner. Expression levels are low in G1 and
increased in S/G2.8 Following mitotic entry Nek2 is targeted
for proteasomal degradation by the APC/C.9 Though Nek2
dimerizes and is rapidly activated by autophosphorylation, it
is kept in the inactive form through dephosphorylation by
protein phosphatase 1 (PP1) until PP1 is inhibited through
binding of inhibitor-2 and phosphorylation by Nek2.10
Several recent reports suggest that Nek2 is abnormally ex-
pressed in cancer cells, and experimental studies have sug-
gested that Nek2 expression contributes to the classic tumor
hallmarks of aneuploidy and chromosome instability.11 Over-
expression ofNek2 leads to premature centrosome separation
and the accumulation of cells with multiple nuclei and super-
numerary centrosomes.12,13 Recent studies suggest thatRNAi
depletion of Nek2 leads to antiproliferative effects, e.g., in
HeLa cells14 and cholangiocarcinoma cell lines.15 RNAi
depletion of Nek2 reduced tumor size and peritoneal dissem-
ination of cholangiocarcinoma tumor xenografts in immuno-
suppressed mice.15 Similarly, genetic knockdown of Nek2
resulted in an antiproliferative and antimigratory phenotype
in MDA-MB-231 breast cancer cells and an antitumor effect
in aMDA-MB-231 xenograft model when the silencing oligo-
nucleotides were injected intratumorally.16 Intriguingly, deple-
tion of Nek2 also synergized with cisplatin in inhibiting
growth of colorectal cancer cells in vitro and in vivo, although
the mechanism for this remains unclear.17 Taken together,
these findings suggest Nek2 as a promising anticancer target.
Although a small molecule inhibitor of the interaction of
Hec1 with Nek2 has been described18 and a Plk1 inhibitor 1
has been shown to have Nek2 activity in a counterscreen
(Figure 1),19 no systematic investigation of Nek2 inhibitors
has been disclosed to our knowledge. We herein report the
exploration of a series of pyrazine-based Nek2 inhibitors
identified through high-throughput screening (HTS).
Results and Discussion
Identification of initial hit compounds was achieved by a
high-throughput biochemical screen20 which furnished pyra-
zine 2 with an IC50 of 0.87 μM (Figure 1). The compound
showed a good overall profile, but we were concerned about
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its low estimated membrane permeability (PAMPA and
CACO-2 assays) andmodest ligand efficiency (binding energy
per heavy atom as described by Hopkins and co-workers)21
(Table 1).
We explored structural modifications around 2 to investi-
gate how the potency, ligand efficiency, and permeability could
be improved. The low permeability of 2 at physiological
pHwas attributed to the carboxylic acid group that predomi-
nantly exists as the carboxylate at this pH.However, the obser-
vation that permeation remained low at pH 5 in the passive
membrane permeability assay (PAMPA) suggested that other
properties contributed to the low permeability, since a signifi-
cantly larger fraction of the compounds should be protonated
under these conditions.We focusedourattentionon the relatively
high topological polar surface area (TPSA,Table 1) of 2, since
it has recently been suggested that polar surface area is a rea-
sonablepredictor for bioavailability andpermeability of acids.22
We therefore began with the removal of the methoxy groups
from the 5-(3,4,5)-trimethoxyphenyl ring as they collectively
represent 23% of the TPSA of 2. Deletion of one methoxy
group led to small drops in activity (3 and 4) (Table 1).
Monomethoxy compound 5, where substitution is meta to
the pyrazine ring, was 4-5-fold less potent, and removal of
both meta 6 or all methoxy groups 7 resulted in a significant
loss of affinity when compared to hit 2. Complete erasure of
the phenyl group 8 affected an approximately 50-fold drop in
activity.
Compounds 4 and 5 were assessed for PAMPA, since they
represented the best compromise between TPSA and Nek2
potency at this stage. Both compounds showed significantly
increased permeability at pH 5 but still low permeability at
physiological pH (Table 1). This suggests that TPSA is pre-
dictive for permeation at pH 5 when the carboxylic acid is
protonated to an extent. We reasoned that good permeability
at pH 5 could be sufficient for reasonable bioavailability
through diffusion from the stomach or duodenum where the
pH is significantly lower than 7.4.
Attention was next focused upon the piperidine ring, and a
number of analogues were prepared (Table 2). Any modifica-
tion of the carboxylic acid, e.g., removal 9or replacementwith
the ester 10, resulted in significant loss of activity, andonly the
primary amide 11 retained some potency.
Having identified the carboxylic acid as a key pharmaco-
phoric point for activity, we decided to replace the piperidine
ring by a phenyl ring, since this offered the advantage of easy
modification. Though the corresponding benzoic acid 12 was
slightly less potent than the HTS hit 2, this result prompted
preparation of substituted benzoic acid derivatives. Addition
of a meta-methyl group 13 conferred a sharp decrease in
inhibition, while having a methyl 14 or methoxy 15 group in
the ortho positionwas tolerated.However, even slightly larger
groups (ethyl instead of methyl 16 and ethoxy instead of
methoxy 17) were not tolerated, suggesting that it was not
viable to improve potency by adding larger groups ortho to
the carboxylic acid.
Our exploration of the SAR so far had shown that the
carboxylic acid is critical for activity and the piperidine ring
can be replaced by phenyl but attempts to improve potency by
substitution of the benzoic acid were not successful. In order
to guide further optimization, the crystal structures of com-
pounds 2, 5, and 12 in the Nek2 catalytic domain were solved.
These structures shared many common features with our
recently reported crystal structure of Nek2.23
The aminopyrazine ring forms two hydrogen bonds with
the hinge region of Nek2, reminiscent of other well-known
kinase inhibitors.24,25 The trimethoxyphenyl group lies copla-
nar at the entrance of the ATP pocket between the hinge
region and the Gly-rich loop (Figure 2a). The contribution
this group has to the potency is explained by the observation
that the phenyl ring is engaging in hydrophobic contacts with
Ile14 and Gly92 in Nek2. Interestingly the single methoxy
group of 5 is unambiguously positioned above Gly91 and
Gly92 (data not shown). Its small but significant effect on
activity might be rationalized by more extensive polar inter-
actions with the hinge, or exclusion of water molecules.
Figure 1. Structures of Plk1 inhibitor 1 demonstrating Nek2 activ-
ity in counterscreen and HTS hit 2.
Table 1. Effect ofModification of the 5-(3,4,5)-TrimethoxyphenylRing
of Inhibitor 2b
aLigand efficiency, calculated according to ref 21. bResults are the
mean ((SD) for ng 3 or the mean values of two independent determinations
with individual determinations in parentheses or samples run at n = 1.
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The piperidine ring of 2 and 5 and the phenyl ring of the
benzoic acid moiety of 12 is sandwiched between the gate-
keeper residueMet86 and Phe148 (Figure 2a). The carboxylic
acid groupof compounds 2, 5, and 12participates in a number
of interactions, including hydrogen bonds with Tyr70 and
Asp159 and a salt bridge with the catalytic lysine (Lys37)
(Figure 2b and Figure 2c).
The Tyr70 residue is remarkable for two reasons: first, it is
rare amongkinases forTyr tobepresent in this position,23 and
second, it shows an unusual conformation in the structures
with 2, 5, and 12. This conformation, which we have referred
to as “Tyr-down”, has so far only been observed for Nek2
bound to inhibitors of this class and apo or ADP-bound
Nek7.23 The fact that the Tyr-down conformation is not
observed with apo Nek2 or Nek2 bound to other types of
inhibitors suggests an induced fit of the binding site by the
class of inhibitors described here. The movement is induced
through interactions between the inhibitor and the protein,
in particular through the hydrogen bond of the carboxylate
to Tyr70 but also through hydrophobic contacts with theMet
gatekeeper. As shown in Figure 3, upon compound binding,
Met86 and Leu59 adopt different positions than in the struc-
tures of Nek2 bound to nucleotides26 and form a pocket that
is occupied by Tyr70 in the tyrosine down conformation.
The implication of the Tyr down conformation will be dis-
cussed below.
The crystal structures revealed another unusual feature of
Nek2: the presence of a Phe (Phe148) at the base of the ATP
pocket. Only 39 of human kinase catalytic domains contain
a Phe in this postion which is usually occupied by Leu inmost
kinases.27 The larger Phe has a profound influence on the
shape of the ATP pocket. It protrudes into the adenine sub-
pocket creating steric hindrance in the plane of the hinge bind-
ing motif. As a result, the piperidine ring of 2 and the phenyl
ring of the benzoic acidmoiety of 12 rotate out of the plane of
the aminopyrazine (50 for the benzoic acid).
This observation also explains why meta substituted ben-
zoic acid derivative 13 is significantly less potent. The 50
rotation of the phenyl ring inevitably results in a steric clash of
the meta substituents with Cys22 on one side or Val68 on
the other side of the catalytic pocket. Also, meta substituents
are going to favor an orthogonal disposition between the
pyrazine and benzoic acid rings, and this is not well tolerated
in the Nek2 active site because of the large Phe residue.
The cocrystal structures of 14, 15, and 17 with Nek2 were
also solved in an attempt to explain the loss of activity with
slightly larger alkyl groups (methoxy in 15 and ethoxy in 17)
(Figure 2). Thebenzoic acid ring of 14was slightly shiftedwith
respect to12away fromTyr70.Also theTyr70 residuewasobser-
ved in both up and down positions in the crystal structure,
indicating that the side chain is mobile in this complex. The
methyl group of compound 14 points toward the back of the
catalytic pocket, in the direction of the hydroxyl group of
Tyr70 in the Tyr-down conformation (Figure 2d).
Surprisingly, the binding mode of 15 represented an inter-
mediate between 12 and 14, with the phenyl ring occupying a
position similar to 14 but with Tyr70 in only the down con-
formation (Figure 2e). The distance between the carboxylic
acid group of the 15 and the hydroxyl group of Tyr70 was 4 A˚
and thus too far to be a hydrogen bond (Figure 2e). The
methoxy group fits compactly in the back of the pocket and
makes contacts with Val68 and Tyr70. This explains why
larger groups cannot be accommodated and perhaps why the
Tyr-down conformation was observed with this compound,
even though the hydrogen bond to Tyr70 is not formed. We
also solved the cocrystal structure of 17, which shows that
the ethoxy group points toward the Gly-rich loop and thus
confirms the hypothesis that this group is too large to be
accommodated in the same position as the methoxy group
of 15 (Figure 2f). The same argument might apply to ethyl
substituted 16which is significantly less active than 14 and 15,
Table 2. Effect of Piperidine/Benzoic AcidModification of Inhibitor 2b
aLigand efficiency, calculated according to ref 21. bResults are the
mean ((SD) for ng 3 or the mean values of two independent determinations
with individual determinations in parentheses or samples run at n = 1.
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but the exact reason is difficult to rationalize as potential
detrimental interactions between the ethyl group of 16 and the
Tyr70 side chain or Val68 cannot be excluded.
The potency (IC50 values) of compounds 13, 16, and 17
coupled with the available cocrystal structures suggested that
substitution of the benzoic acid moiety leads to steric repul-
sion invoked by Phe148 induced 50 rotation of the phenyl
ring. As mentioned above, Phe is a rare and large residue in
this position and has a profound influence on the shape of the
ATP pocket. This and the large gate keeper (Met86) induce
strong geometric constraints. As a result, only limited space
remains for additional interactions between the inhibitor and
the kinase, posing a significant challenge to improve affinity.
Only three other kinases with a Phe in this position have
been crystallized with inhibitors (Braf, Wee1, and Plk1). A
particularly relevant example to Nek2 is Plk1, which features
not only a relatively large Leu gate keeper but also aCys in the
position equivalent to that of Cys22 in Nek2. (Figure 2).
Interestingly, the relevance of the equivalent Phe (Ph183 in
Plk1) for inhibitor binding has recently been described.28,29
Weanalyzed the available cocrystal structures of Plk1 in order
to gain insights into how activity in our series can be improved.
A pertinent example was the cocrystal structure of Plk1 with
BI-2536 (18) (Figure 4).This inhibitor engages in ahydrophobic
interactionwith thePhe 183 comparable to our inhibitorswith
Phe148 in Nek2.28 In addition, a derivative of 18 has been
described to show significant activity against Nek2.28
This structureoffered some inspiration as tohowadditional
potency againstNek2 canbe derived: two alkyl groups, a cyclo-
pentyl group and an ethyl group, of 18 reach into the region
to the side of and behind Phe183 (corresponding to Phe148 in
Nek2), respectively (Figure 4a). These groups engage in hydro-
phobic interactionswith the kinase, very likely contributing to
activity.28 We reasoned that it should be possible to mirror
Figure 2. Bindingmode of pyrazine inhibitors inNek2 catalytic pocket. (a) Compound 2 (C in yellow): The trimethoxyphenyl group is located
between Ile14 of the Gly-rich loop (green) and Gly91-Gly92 of the hinge region (purple). The piperidine ring is sandwiched between Phe148
and the gatekeeper residueMet86. The aminopyrazine ring forms twohydrogen bondswith the hinge region.Compounds 2 (b) and 12 (c) (C in cyan):
The carboxylic acid interacts with Tyr70, Lys37, and Asp159. For substitutions of the phenyl ring, the methyl group of 14 (d) (C in lavender)
andmethoxy group of 15 (e) (C in orange) showdiffering effects on the Tyr70 conformation. In contrast with 14 and 15, a larger substituent, the
ethoxy group of compound 17 (f) (C in mint), points toward the Gly-rich loop. Residues Cys22 in (a) and (b) and Tyr70 in (d) and (f) are
depicted with alternative conformations. Modifications on the piperidine ring do not have any effect on the remaining interactions with Nek2.
All distances are in A˚.
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these interactions onNek2 due to the sequence similarity with
Plk1 in this region of the kinase.
As reported above, substituted benzoic acids did not improve
activity.However, substitution of the phenyl group is only possi-
ble in the plane of the aromatic ring and this potentially results in
a steric clashwithCys22.Ontheotherhand, the sp3 centersof the
piperidine ring of compound 2 offered the possibility of placing
substitution at a different angle relative to the ring.
We thus explored substitution of the piperidine of 2 starting
with the racemic cis and trans methyl substituted compounds
19 and 22 (Table 3). While trans-substitution led to a small
drop in activity, cis-substitution was equipotent to 2. Extend-
ing frommethyl to ethyl (23 and 24) resulted in a small loss of
activity in the cis case and a significant loss in the trans case.
Since cis-substitution was preferred, additional substituted
piperidines were prepared. Disappointingly, groups larger
than ethyl led to an even larger loss of inhibition (25 and 26).
As the cis ethyl group was the largest group still tolerated,
the crystal structure was solved after soaking Nek2 with
racemic 23 (Figure 4b). Interestingly, only theR,R enantiomer
could be mapped to the electron density, suggesting that this
enantiomer is significantly more active than the other enan-
tiomer. The ethyl group points upward toward Cys22, and
the piperidine maintains a slightly different conformation
compared to 2. The side chain of Cys22, which adopts two
conformations in 2, has shifted to a single conformation
creating a small pocket that accommodates the ethyl group
analogous with Cys67 in the cocrystal structure of Plk1 with
18.28 The crystal structure of 23 also offered an explanation
why 25and 26were significantly less active: the largern-propyl
and cyclopropyl groups very likely clash with Cys22.
The two enantiomers of 19were separated by chiral HPLC.
As expected, they showed very different inhibition. Enantio-
mer (-)-20 was 10 less potent than the HTS hit 2, while
enantiomer (þ)-21gave an IC50of 0.39( 0.18μM(n=4).The
absolute stereochemistry of this enantiomer was not assigned.
However, the observation that only the R,R enantiomer was
observed in the crystals structure of ethyl substituted 23
suggests that the more active (þ) enantiomer 21 features the
same R,R stereochemistry. The slightly enhanced activity
provided by the methyl group in 21 may be the result of an
improved balance between additional beneficial hydrophobic
contacts and repulsive interactions.
Superimposition of compound 23with the above-mentioned
structure of 18 bound to Plk1 indeed showed that the ethyl
groups of the two compounds aligned closely (Figure 4b).
Furthermore, the comparison suggested that substitution of
an equatorial proton of the piperidine ring of inhibitor 19
or 23 by an alkyl group could mimic the cyclopentyl group of
the Plk1 inhibitor 18, leading to improved affinity. This equa-
torial position translates into the cis isomer with respect to the
carboxylic acid, and we thus prepared a small series of com-
pounds with hydrophobic groups attached to the 2-position
(cis) of the piperidine ring.
While the racemic mixtures of compounds 27 and 28 gave
comparable potency, propyl derivatives 29 and 30 led to a
significant loss of activity. This loss could be explained by
intramolecular steric repulsion between the alkyl groups and
the pyrazine ring in the bioactive conformation resulting in a
Figure 3. Opening of the Tyr70-down pocket by movement of
Met86 upon inhibitor binding to Nek2. Tyr70-down conformation
observed in Nek2 inhibitor-bound structure (gray) is sandwiched
betweenMet86 “gatekeeper” and Leu59 of the C-helix. Compound
2 C is in yellow, and nucleotide bound Nek2 structure (PBD code
2W5H) is in teal.
Figure 4. (a) Binding of BI-2536 (18) inhibitor (C in light yellow) to Plk1 (PDB code 2RKU). The ethyl group of BI-2536 is located in a small
pocket between residues Cys67 (Cys22 in Nek2), Lys82 (Lys37 in Nek2), and the gatekeeper Leu130 (Met86 in Nek2). (b) Crystal structure of
BI-2536 in Plk1 superimposedwith the cocrystal structure of 23 inNek2. Ethyl group of 23 andBI-2536 (18) point toward the same small pocket
into the kinase catalytic site.
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Table 3. Effect of Addition of Alkyl Groups to the Piperidine Ring of Inhibitor 2b
aLigand efficiency, calculated according to ref 21. bResults are the mean ((SD) for n g 3 or the mean values of two independent determinations with
individual determinations in parentheses or samples run at n = 1.
7688 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 21 Whelligan et al.
penalty to adopt this conformation. The Plk1 inhibitor 18 is
rigid, and no penalty is incurred in this case.
Alternatively, a steric clash between the propyl groups of
29 and 30 and Phe148 might lead to a reduced IC50 despite
additional hydrophobic contacts. In any case, methyl repre-
sented the most active alkyl substiuent at the 2-position (cis)
within this series.
To complete the SAR around the piperidine carboxylic
acids, we combined the results of the 2- and 3-substitutions
by preparing the cis dimethyl-substituted derivative. The two
enantiomers were separated by chiralHPLCand showed very
different activities (Table 3). The (-) enantiomer 31 was the
most active compound prepared so far, while the (þ) enantio-
mer 32 was somewhat less active than parental compound 2.
Unfortunately, all attempts to obtain a cocrystal structure
of 31 failed and we were thus not able to unambiguously
determine the absolute stereochemistry. However, if it is
assumed that the 3-substiuent of 31 adopts the same stereo-
chemistry as the ethyl group in the cocrystal structure of 23,
the absolute stereochemistry can be assigned as R,R,R.
In this absence of a cocrystal structure it is also difficult to
judge whether the 4-fold improvement of 31 compared to
2 results from additional hydrophobic contacts or whether
conformational locking also plays a role.
After optimization of the right side of the molecule to give
a 4-fold improvement in potency by the addition of twomethyl
groups, itwasdecided to refocuson the left side of themolecule.
Because of relative ease of synthesis, the unsubstituted piper-
idine acid was maintained for this purpose. Interestingly, the
fragment-type compound 8 described above had shown the
best ligand efficiency in this series so far. The introduction of
thephenyl ring7 leads to amorepotent but less ligand efficient
compound. It was envisaged that isosteric replacement of this
group may lead to better ligand efficiency. The crystal struc-
ture of compound 5 in Nek2 shows a coplanar conformation
between the phenyl and the pyrazine ring. It was decided to
replace the phenyl ring with isosteric thiophene, since this
should be able to engage in similar hydrophobic interaction as
the phenyl ring and should relax steric interactions of the
protons in this coplanar conformation. Indeed, thiophene
33 and in particular 34 showed good activity when compared
to the unsubstituted phenyl compound 7 (Table 4).
Additional hydrophobic substitutions on the thiophene
were explored with the aim of improving activity without
increasing TPSA. This was focused on the ortho position with
respect to the pyrazine ring, since docking of compound 34
intoNek2 (data not shown) suggested that the other positions
would point toward solvent.
Gratifyingly, substitution with an ethyl 35 or cyclopropyl
36 group led to an approximately 4-fold improvement in
potency. Cyclopentyl compound 37 was slightly less active but
still comparable to the unsubstituted thiophene derivative 34.
We solved the cocrystal structure of compounds 35 and 36
with Nek2 (Figure 5). The ethyl group of 35 and the cyclo-
propyl group of 36 point toward the hinge region and occupy
a hydrophobic pocket between Ile14 and Gly91-Gly92 simi-
lar to the methoxy group of compound 5. This observation
explains why groups larger than cyclopropyl in this position
lead to loss of activity, since they cannot be accommodated in
the same pocket because of steric repulsion.
Thiophene compounds35 and 36were submitted forPAMPA
assay along with dimethylpiperidine 31. All thiophenes showed
improved permeation at pH 5 compared to hit compound 2 but
still low permeation at physiological pH (Table 4).
Unfortunately, the low permeation observed with all
carboxylic acids described here at pH 7.4 correlated with
a lack of effect in our cell based assay (IC50>50 μM), which
we recently described elsewhere20 (data not shown), and we
thus decided not to pursue this series further. However, we
were intrigued by our observation of the Tyr-down con-
formation and decided to further investigate its significance
for Nek2 inhibition. In this context, it is worth noting that
we crystallized the unphosphorylated form of the kinase
and that it is unlikely that the Tyr-down conformation
would be adopted by the phosphorylated, fully active form.
Unfortunately, all our attempts to crystallize the phosphory-
lated form of the kinase were unsuccessful. The activation loop
will become more ordered (in a DFG-in conformation) upon
phosphorylation, disfavoring the changes in the DFG motif
associatedwith theTyr-down conformation. Furthermore, this
will bring the C helix and in particular a Leu residue (Leu59)
closer to the gatekeeper, closing the hydrophobic pocket filled
by Tyr70 in the Tyr-down conformation and forming the
hydrophobic spine that is a feature of active kinase structures.30
As a result, this part of the ATP pocket possibly adopts a
Table 4. Replacement of the 3,4,5-Trimethoxyphenyl Ring of 2 by
Thienyl Substituentsb
aLigand efficiency, calculated according to ref 21. bResults are the
mean ((SD) for ng 3 or the mean values of two independent determinations
with individual determinations in parentheses or samples run at n = 1.
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significantly different shape once the kinase has autophos-
phorylated.
However, inhibitorsbinding to the inactiveTyr-downconfor-
mation should be capable of inhibitingNek2 autophosphoryla-
tion and activation. Inhibition of Nek2 autophosphorylation
would be pharmaceutically desirable, since Nek2 is present in
the unphosphorylated form during most of the cell cycle.
The kinase assay employed in this study so far was per-
formed using the unphosphorylated kinase. Addition of ATP
after preincubationwith the compound initiates the cascadeof
trans-autophosphorylation on Thr175 and subsequent sub-
strate phosphorylation (Figure 6).
This assay format therefore detects compounds that inhibit
autophosphorylation and/or substrate phosphorylation. To
further investigate the relevance of the Tyr-down conforma-
tion for Nek2 inhibition, a set of experiments was performed
to test if a representative set of our compounds (2, 12, 14, 15,
31, and 35) inhibit autophosphorylation or substrate phos-
phorylation or both. First, the kinase activity assay was
performed by preincubation of the kinase with ATP to ensure
complete phosphorylation of the enzyme before incubation
with the inhibitor. This procedure only identifies inhibitors of
substrate phosphorylation (step 2 in Figure 6). Second, a
specific assay was developed to measure the autophosphory-
lation reaction using an antibody that recognizes the phos-
phorylated Thr175 ofNek2. Thus, this assay can only identify
inhibitors of autophosphorylation (step 1 in Figure 6).
These results are shown in Table 5. All compounds inhibit
autophosphorylation and substrate phosphorylation with
comparable potencies. The significant inhibition of autopho-
sphorylation suggests that the inactive Tyr-down conformation
observed in our cocrystal structure is indeed relevant for inhib-
itor design. The autophosphorylation data for compounds 14
and 15 are particularly noteworthy. Compound 14 inhibits
autophosphorylation. However, as described above, in the
cocrystal structure of 14 Tyr70 adopts more than one con-
formation. This observation indicates that potent inhibition
of autophosphorylation does not require locking Tyr70 into
the down conformation. Loss in enthalpy, e.g., caused by
the breakage of interactions between the inhibitor and Tyr70,
might be compensated by gain in entropy due to additional
degrees of freedom of Tyr70.
As described above, 15 binds to the tyrosine down con-
formation, but the distance between the carboxylic acid group
of 15 and the hydroxyl group of Tyr70 is too large (4 A˚) for a
hydrogen bond. The observation that this compound never-
theless shows activity in the autophosphorylation assay com-
parable to 12 and 14 indicates that other interactions, e.g.,
additional hydrophobic interactions between the methoxy
group and the protein (Val68/Tyr70), compensate for the loss
of the hydrogen bond.
These data emphasize the importance of structural data,
since the observation that 12, 14, and 15 interact differently
with Nek2 cannot be derived from biochemical data only.
Our data also suggested that compounds of this series can
inhibit the kinase in both the phosphorylated and unphos-
phorylated states, which is ideal because it ensures that these
inhibitors can bind to the enzyme and inhibit it during its
entire lifespan, regardless of the phosphorylation stage.
To conclude our initial investigations, compounds 2, 31,
and 35 were submitted for selectivity testing against Nek1,
Plk1, and Chk1 (Table 6). Nek1 was chosen because it is the
closest homologue toNek2 and has several cellular functions,
including ciliogenesis and DNA repair.31,32 Plk1 was chosen
because it also features a Phe in the Phe148 equivalent posi-
tion and because we wanted to avoid the effects associated
with Plk1 inhibition. Chk1 was chosen because it is a cell cycle
kinase without similarity to Nek2. The data are shown in
Table 6. All compounds show good selectivity against Chk1,
Figure 5. Ethyl group of compound 35 (C in green) and cyclopropyl
group of compound 36 (C in orange) point toward the back of the
catalytic pocket and are sandwiched between Ile14 of the Gly-rich
loop and Gly91-Gly92 of the hinge region.
Figure 6. Autophosphorylation and substrate phosphorylation cas-
cade. Addition of ATP to the inactive Nek2 dimer initiates trans-
autophosphorylation on Thr175 and activation of the protein. This
active form of Nek2 can then phosphorylate its substrate.
Table 5. Potency of Selected Compounds against Nek2Autophosphor-
ylation and Substrate Phosphorylationa
IC50 (μM)
compd Tyr70
Nek2
autophosphorylation
Nek2 substrate
phosphorylation
2 Tyr down 0.41 ( 0.14 0.94 (0.77, 1.1)
12 Tyr down 0.71 (0.56, 0.85) 1.6
14 Flexible 1.2 (1.0, 1.3) 2.3 (1.9, 2.7)
15 Tyr down 1.3 ( 0.3 2.5
31 0.3 0.2
35 Tyr down 0.72 1.9
aResults are the mean ((SD) for n g 3 or the mean values of two
independent determinations with individual determinations in paren-
theses or samples run at n= 1.
Table 6. Selectivity Data of Selected Compounds against Nek1, Plk1,
and Chk1a
IC50 (μM)
compd Nek2 Nek1 Plk1 Chk1
2 0.87 ( 0.34 2.6 ( 1.1 22.6 ( 4.5 >100
31 0.23 (0.19, 0.26) 0.17 (0.14, 0.19) 19.4 (15.1, 23.6) >100
35 2.1 ( 1.0 22.5 (15.6, 29.4) 8.5 (5.5, 11.4) >100
aResults are the mean ((SD) for n g 3 or the mean values of two
independent determinations with individual determinations in paren-
theses or samples run at n= 1.
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which is not surprising given that Chk1 and Nek2 belong to
different kinase families and are not closely related in terms of
sequence.
A different picture emerged for Plk1 and Nek1. Hit com-
pound 2 showed encouraging selectivity against Plk1, but thio-
phene 35 was less selective. The enhanced selectivity of com-
pound 2 can be rationalized by the presence of the methoxy
groups.The cocrystal structures of both compounds indicated
that the methoxy groups are situated aboveGly91 andGly92.
Plk1 features an Arg (Arg136) instead of Gly92 in Nek2,
possibly leading to a steric clash with the methoxy group. The
lack of selectivity of the thiophene derivative could therefore
potentially be rectified by substitutionoff the thiophene toward
Gly92. The improved activity of compound 31 translates into
good selectivity (approximately 100-fold), again demonstrat-
ing that very good selectivity against Plk1 can be achieved in
this series.
Finally all compounds showsignificant activity againstNek1,
which is not surprising given that the sequences of Nek1 and
Nek2 in the ATP pocket are identical except for anAla toCys
switch (Cys22 in Nek2). However, compound 35 shows an
approximately 10-fold selectivity againstNek1. In the absence
of a Nek1 crystal structure this selectivity is difficult to
rationalize.
In conclusion, to the best of our knowledge, we have
described the first systematic investigation of the structure-
activity relationship of inhibitors of the mitotic kinase Nek2.
We prepared several analogues of the aminopyrazine 2 by
exploring structure-based design. Substitution on the piper-
idine ring led to compound 31 as themost active compound to
date with good selectivity against Plk1. Replacement of the
trimethoxyphenyl group of 2 by thiophene derivatives led to
compounds with improved permeation.
The cocrystal structures presented here reveal that the
pyrazine based inhibitor 2 and several of its analogues bind
to anunusual inactive conformationofNek2 referred to as the
Tyr-down conformation. To our knowledge, the Tyr-down
conformation has so far not been observed with any other
class of kinase inhibitors. Our biochemical data confirm that
these compounds inhibit autophosphorylation, as would be
predicted for an inhibitor of the inactive kinase, supporting
the hypothesis that this conformation can be explored for the
design of autophosphorylation inhibitors.
A key feature ofNek2 is Phe148which because of its central
position in the ATP pocket and in concert with the large
gatekeeper residue (Met86) profoundly affects inhibitor design.
Very few other kinases possess this combination of a phenyl-
alanine in this position and a large gatekeeper. One example
is Plk1, and the cross-reactivity of compound 35 against
Plk1 as well as the Nek2 activity in the recently published
Plk1 inhibitors19,28 suggests that these kinases, which do
not belong to the same kinase family, can be inhibited by
similar chemotypes. We believe that this is at least partially
due to the rare combination of this particular Phe and a large
gatekeeper.
Interestingly, only very few potent Nek2 inhibitors have
been published to date. We hypothesize that the strong
geometric constraints introduced by the combination of Phe
in this central position and the large Met gate keeper residue
make Nek2 challenging to target, requiring an “exquisitely
matched” inhibitor as observed for BI-2536 (18) in the case of
Plk1.28 We believe that our study presented here will aid the
identification of more advanced inhibitors of Nek2 featuring
such an exquisite match.
Chemistry
Compounds 2-8, 10, and 33-34 were prepared from
common intermediate 39 (Scheme 1) which was formed by
regioselective SNAr reaction of methyl piperidine-4-carboxy-
latewith commercially available 3,5-dibromopyrazin-2-amine
(38). Reaction with the required phenylboronic acid under
Suzuki conditions afforded the elaborated tricyclic core of the
inhibitors. In the case of compound 40f, dehalogenation was
achieved by hydrogenation. Standard basic hydrolysis pro-
vided the final compounds in acceptable yields.
Modification of the right-hand side of the structure was
achieved through use of common intermediate 42 (Scheme 2).
This was constructed by chemoselective Suzuki coupling of
5-bromo-3-chloropyrazin-2-amine (41) with 3,4,5-trimethoxy-
phenylboronic acid. Subsequent SNAr reaction with cyclic
amines provided compounds 9 and 11. Alternatively, com-
pounds 12-17 were prepared by a second Suzuki coupling
followed by base hydrolysis.
Synthesis of the 3-substituted piperidine compounds 19-26
is outlined in Scheme 3. Triflation of commercially available
protected oxopiperidine 43 gave enol triflate 44, which was
used in either a Negishi33 (45a-c) or Suzuki (45d) coupling to
provide alkylated tetrahydropyridine intermediates. Deben-
zylation using ACE-Cl34 andMeOH followed by hydrogena-
tion using a platinumcatalyst afforded the free amines 46a-d.
These were reacted with dihalopyrazine 41, in a similar SNAr
procedure as previously described, to afford the desired pro-
ducts 47a-d chemoselectively. Suzuki coupling with 3,4,5-
trimethoxyphenylboronic acid and hydrolysis of the ester
gave the cis 3-substituted piperidine compounds 19, 23, 25,
and 26. Interestingly, hydrolysis of 3-cyclopropyl substituted
compound 48d under the usual basic conditions was unsuc-
cessful and it was necessary to employ acidic conditions.
Chiral HPLC resolution of ester 48a followed by hydrolysis
in the same manner afforded the enantiomerically pure
Scheme 1. Synthesis of Compounds 2-8, 10, 33, and 34a
aReagents and conditions: (a)methyl piperidine-4-carboxylate,DIPEA,
NMP,microwave, 140 C. (b) For 10 and 40a-e: ArB(OH)2, Pd(PPh3)4,
2MNa2CO3 (aq),DME,microwave, 100 C. (c) For 40f: H2, 10%Pd/C,
EtOH, room temp. (d) For 40g-h: ArB(OH)2, Pd(dppf)Cl2 3CH2Cl2,
2 M Na2CO3 (aq), DME, microwave, 105 C. (e) For 2-8: 1 M NaOH
(aq), THF, room temp. (f) For 33-34: 1 M NaOH (aq), MeOH, 65 C.
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compounds 20 and 21. Compounds 22 and 24were formed by
epimerization of the respective ester intermediates by prolonged
heating with sodium ethoxide (to give the more energetically
favored trans diastereoisomers)35 followed by basic hydrolysis.
2-Methyl substituted piperidine compound 27was prepared
in four steps beginningwith hydrogenation ofmethyl 2-chloro-
6-methylisonicotinate (49) (Scheme 4). The resulting piper-
idine 50 reacted very poorly under standard SNAr conditions,
possibly because of the increased steric bulk around the
nucleophilic center. However, use of dibromopyrazine 38, in
place of 3-chloro-5-bromopyrazine 41, along with silver oxide
and prolonged heating at 180 C provided adequate product
(as the hydrolyzed ester), albeit in 6% yield, to complete the
synthesis of 27 after re-esterification, Suzuki coupling, and
base hydrolysis. The regioselectivity of the SNAr reaction was
confirmed in the final product by observation of a NOE
Scheme 2. Synthesis of Compounds 9 and 11-17a
aReagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid, Pd(dppf)Cl2 3CH2Cl2, 2 M Na2CO3 (aq), DME, microwave, 80 C; (b) R2NH,
DIPEA, NMP, microwave, 180 C; (c) ArB(OR)2, Pd(dppf)Cl2 3CH2Cl2, 2 MNa2CO3 (aq), DMF, microwave, 130 C; (d) 1 MNaOH (aq), MeOH, 60 C.
Scheme 3. Synthesis of Compounds 19-26a
aReagents and conditions: (a) NaH, Et2O, Tf2O. (b) For 45a,b: R2Zn, Pd(PPh3)4, room temp. (c) For 45c: i-Pr2Zn, Pd(PPh3)4, room temp. (d) For
45d: c-PrB(OH)2, Pd(OAc)2, PCy3, K3PO4, toluene/water (9:1), microwave, 140 C. (e) (i) ACE-Cl, DCE, reflux; (ii) MeOH, reflux; (f) H2, 50 psi, PtO2,
AcOH, 50 C; (g) 41, DIPEA, NMP, microwave, 140 C; (h) 3,4,5-trimethoxyphenylboronic acid, Pd(dppf)Cl2 3CH2Cl2, 2 M Na2CO3 (aq), DME,
microwave, 100 C. (i) For 19, 23, and 25: 1 MNaOH (aq), MeOH, 60 C. (j) For 26: HCl, THF/H2O (1:1), 70 C; (k) (i) NaOEt, EtOH, reflux; (ii) 1 M
NaOH (aq), MeOH, 60 C.
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between the protons at the 2/6-positionof the trimethoxyphenyl
group and the pyrazine proton.
The synthesis of alternative 2-alkyl substituted piperidines
28-32was achieved by either iron(III) catalyzed alkylation36
(54a and 54c) or Suzuki coupling (54b) of chloropyridine
52 followedbyhydrogenationwithaplatinumcatalyst (Scheme5).
2,3-Dimethylpiperidine 55d was synthesized by hydrogena-
tion of dimethylpyridine 54dwhich was formed by reaction of
dimethyloxazole 53 with methyl acrylate.37 Given the diffi-
culty encountered in SNAr reaction of 2-methylpiperidine 50
with halopyrazines, an alternative route to compounds 28-32
was devised involving regioselective SNAr reaction with the
more reactive PMB-protected dichloropyrazinone 56.38,39
Installation of the trimethoxyphenyl group was achieved
through Stille coupling,40 as this does not require a base like
the corresponding Suzuki reaction which led to decomposi-
tion of the starting material. PMB deprotection did not occur
withTFAat reflux, but the use of 3.5 equiv of trifluoromethyl-
sulfonic acid (TfOH) promoted the reaction at room tem-
perature to furnish the tricylic core. Unfortunately, treatment
of the pyrazinone with iodoacetamide41,42 did not convert it
directly to the aminopyrazine, as planned, necessitating a
more protracted route involving triflation, Buchwald cou-
pling with PMB-amine, and deprotection using TfOH. Finally,
basic hydrolysis afforded the desired compounds 28-30.
Compounds 31 and 32 were prepared by hydrolysis of the
corresponding enantiomerically pure esterswhichwere obtained
from chiral HPLC separation.
The alkylthiophene compounds 35-37were synthesized by
Suzuki coupling of the appropriate 3-alkyl-2-bromothiophene
with pyrazineboronic acid 61 followed by hydrolysis of the
ester (Scheme 6). The 3-alkyl-2-bromothiophenes were made
by regioselective bromination43 at the 2-position of commer-
cially available 3-ethylthiophene (59a), 3-cyclopropylthiophene
(synthesized by Suzuki coupling of cyclopropylboronic acid
with 3-bromothiophene),44 or 3-cyclopentylthiophene.45 The
pyrazinylboronic acid coupling partner was made from bro-
mopyrazine 39 using palladium catalysis and was used crude.
Experimental Section
Nek2CaliperMethodology.Kinase activitywasmeasured in a
microfluidic assay that monitors the separation of a phosphory-
lated product from its substrate. The assay was run on a Caliper
EZ Reader II (Caliper Life Sciences Ltd., Runcorn, U.K.) using
separation buffer (no. 760367 Caliper LS) containing CR-8
(500 nM, no. 760278, Caliper LS). In 384-well polypropylene
plates (no. 781280, Greiner Bio-One, Gloucestershire, U.K.),
compound stocks (10mM)were diluted 1:4 in 100%DMSOand
then sequentially diluted 1:3 in DMSO to make an eight-point
dilution curve (2500-1.1 μM). The compounds were further
diluted 1:20 into kinase buffer (50 mM HEPES, 0.02% NaN3,
0.01%BSA, 0.1mM sodium orthovanadate, 1mMDTT, 5mM
MgCl2, 0.1% Tween 20) before 4 μL was transferred into a
384-well polypropylene assay plate, equivalent to a final con-
centration range of 50-0.02 μM in 2% DMSO.
Scheme 4. Synthesis of Compound 27a
aReagents and conditions: (a) H2, H-Cube, 10%Pt/C, AcOH, 70 C;
(b) 38, Ag2O, DIPEA, NMP, microwave, 180 C; (c) 3,4,5-trimethoxy-
phenylboronic acid, Pd(dppf)Cl2 3CH2Cl2, 2 M Na2CO3 (aq), DME,
microwave, 100 C; (d) 1 M NaOH (aq), MeOH, 60 C.
Scheme 5. Synthesis of Compounds 28-32a
aReagents and conditions. (a) For 54a and 54c: RMgBr, Fe(acac)3,
THF/NMP (9:1), room temp. (b) For 54b: (i) isopropenylboronic acid
pinacol ester, Pd(OAc)2, SPhos, K3PO4, MeCN/H2O (3:2), microwave,
130 C; (ii) MeOH, HCl, reflux. (c) For 54d: methyl acrylate, hydro-
quinone, benzene, reflux. (d) H2, 50 psi, PtO2, 50 C; (e) DIPEA, NMP,
microwave, 140 C; (f) (3,4,5-trimethoxyphenyl)tributyltin, Pd2(dba)3,
SPhos, CsF, MeCN, microwave, 160 C; (g) CF3SO2OH, TFA/CH2Cl2
(1:1), room temp; (h) Tf2O, DIPEA, CHCl3, room temp; (i) PMB-NH2,
Pd(OAc)2, BINAP, K3PO4,MeCN,microwave, 110 C; (j) CF3SO2OH,
TFA/DCM (1:1), room temp; (k) 1 M NaOH (aq), MeOH, 60 C.
Scheme 6. Synthesis of Compounds 35-37a
aReagents and conditions: (a) NBS, AcOH, CHCl3, room temp;
(b) bis(pinacolato)diboron,Pd(dppf)Cl2 3CH2Cl2,KOAc,DMF,microwave,
105 C; (c) Pd(dppf)Cl2.CH2Cl2, 2 M Na2CO3 (aq), DME, microwave,
105 C; (d) 1 M NaOH (aq), MeOH, 65 C.
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To this assay plate, Nek2 (2 μL, 4 nM final, no. PV3360
Invitrogen), peptide 11 (5-FAM-KKLNRTLSVA-COOH, 2 μL,
1 μMfinal, no. 760355Caliper LS), andATP (2 μL, 30 μMfinal)
all diluted in kinase buffer were added. The plate was sealed and
centrifuged (1 min, 1000 rpm) before incubation for 1 h at room
temperature. The reaction was stopped by the addition of sepa-
ration buffer (90 μL). The plate was read on an EZ Reader II
(Caliper LS) using a 12-sipper chip (760137-0372R, Caliper LS)
using instrument settingsofpressure-1.8psi andvoltage 1850ΔV.
The percentage conversion of product from substrate was gene-
rated automatically by the instrument, and the percentage
inhibition was calculated relative to blank wells (containing no
enzyme and 2%DMSO) and total wells (containing all reagents
and 2% DMSO). IC50 values were calculated in GraphPad
Prism 5 using a nonlinear regression fit of the log (inhibitor)
versus response with variable slope equation.
Nek2 Autophosphorylation Assay. Autophosphorylation activ-
ity was measured in a DELFIA assay that monitors autophos-
phorylationofNek2using a specific phospho-Nek2antibody.This
antibodywas raised to the T175 autophosphorylation site of Nek2
by immunizing rabbits with a CSFAKT(P)FVGTPE peptide
(synthesied by J Metcalfe, ICR) conjugated to KLH and affinity
purified prior to use (Open Biosystems, Huntsville, AL, USA).
In 384-well polypropylene plates (no. 781280, Greiner Bio-One,
Gloucestershire, U.K.), compound stocks (10 mM) were diluted
1:4 in 100%DMSOand then sequentially diluted 1:3 inDMSO to
make an eight-point dilution curve (2500-1.1 μM). The com-
pounds were further diluted 1:20 into kinase buffer (50 mM
HEPES, 0.02% NaN3, 0.01% BSA, 0.1 mM sodium orthovana-
date, 1mMDTT, 5mMMgCl2) before 20 μLwas transferred into
a 384-well polypropylene assay plate equivalent to a final concen-
tration range of 50-0.02 μM in 2% DMSO. To this assay plate,
Nek2 (10 μL, 4 nM final, no. PV3360 Invitrogen) was added. The
plate was then briefly shaken and incubated for 5 min at room
temperature. The reaction was started with the addition of ATP
(20 μL, 30 μMfinal). After 50 s of incubation time the reactionwas
stopped by the addition of stop buffer (50 μL, 50 mM HEPES,
0.02%NaN3 , 0.01%BSA, 0.1mMsodiumorthovanadate, 1mM
DTT, and 10 mM EDTA). The reaction mixture (50 μL) was
transferred to an Immulon 2 high bind plate (no. 3455, Thermo
Scientific, Loughborough, Leicestershire, U.K.) and left to coat
overnight at 4 C. The plates were washed four times with wash
buffer (0.1%Tween 20,WellWash4, ThermoLife Sciences) before
being blocked with 5%milk in PBS (100 μL) for 30 min at 37 C.
The plate was washed a further two times with wash buffer before
the additionof primary phospho-T175 antibody (50μL).The plate
was incubated for 2 h at 37 C.The platewaswashed a further four
timeswithwashbufferbefore theadditionofeuropiumlabeledsecon-
dary antibody (50 μL, no. AD0105, anti-rabbit IgG, 0.25 μg/mL
final, PerkinElmer Life Sciences, Seer Green, Buckinghamshire,
U.K.) diluted inDELFIAassaybuffer (no. 4002-0010,PerkinElmer
Life Sciences). The plates were washed a further four times with
wash buffer before the addition of enhancement solution (no.
4001-0010, 50 μL/well, PerkinElmer Life Sciences). The plate was
read on an Envision 2103 multilabel counter (PerkinElmer Life
Sciences) using a time-resolved measurement mode reading fluo-
rescence at 615 nm. The percentage inhibition was calculated
relative to blank wells (containing no enzyme and 2% DMSO)
and total wells (containing all reagents and 2% DMSO). IC50
values were calculated in GraphPad Prism 5 using a nonlinear
regression fit of the log (inhibitor) versus response with variable
slope equation.
Plk1 Caliper Methodology. In 384-well polypropylene plates
(Greiner Bio-One, Gloucestershire, U.K.), compound stocks
(10 mM) were diluted 1:2 in 100%DMSO and then sequentially
diluted 1:3 in DMSO to make an eight-point dilution curve
(5000-2.3 μM). The compounds were further diluted 1:20 into
kinase buffer (50 mM MOPS, pH 6.5, 0.004% Triton-X-100,
1 mMDTT, 5 mMMgCl2) before 4 μL was transferred into a 384-
well polypropylene assay plate equivalent to a final concentration
range of 100-0.046 μM in 2% DMSO. To this assay plate, Plk1
(2 μL, 18 nM final, 05-157, Carna Biosciences-Kinase Logistics
ApS, Denmark), peptide (5-FAM-RRRAGALMDASFEEQ-
CONH2, 2 μL, 2 μM final, Pepceuticals, Nottingham, U.K.), and
ATP (2 μL, 15 μM final) all diluted in kinase buffer were added.
The plate was sealed and centrifuged (1 min, 1000 rpm) before
incubation for 75 min at room temperature. The reaction was
stopped by the addition of separation buffer (70 μL). The plate
was read in the same manner as for Nek2.
Nek1 Caliper Methodology. In 384-well polypropylene plates
(Greiner Bio-One, Gloucestershire, U.K.), compound stocks
(10 mM) were diluted 1:2 in 100%DMSO and then sequentially
diluted 1:3 in DMSO to make an eight-point dilution curve
(5000-2.3 μM). The compounds were further diluted 1:20 into
kinase buffer (50mMHEPES, 0.02%NaN3, 0.01%BSA, 0.1mM
sodiumorthovanadate, 1mMDTT, 5mMMgCl2, 0.1%Tween 20)
before 4 μL was transferred into a 384-well polypropylene
assay plate equivalent to a final concentration range of 100-
0.046 μM in 2%DMSO. To this assay plate, Nek1 (2 μL, 4 nM
final, PV4202 Invitrogen), peptide 11 (5-FAM-KKLNRTLSVA-
COOH, 2 μL, 1 μMfinal, no. 760355 Caliper LS), andATP (2 μL,
60 μM final) all diluted in kinase buffer were added. The plate
was sealed and centrifuged (1 min, 1000 rpm) before incubation
for 1 h at room temperature. The reaction was stopped by the
addition of separation buffer (90 μL). The plate was read in the
same manner as for Nek2.
TPSA. Molecular polar surface area was calculated using
Pipeline Pilot, version 7, incorporating nitrogen, oxygen, phos-
phorus, and sulfur as described.46
Cocrystallization of Nek2 with Ligands. Structures were experi-
mentally determined as previously described.23
General Chemistry Information. Starting materials, reagents,
and solvents for reactions were reagent grade and used as pur-
chased. Microwave experiments were conducted using a CEM
Discover synthesis unit. The machine provides a continuous
focused microwave delivery system. The power output can be
varied from 0 to 300 W. Reactions were performed in glass
vessels (∼10 mL) sealed with a septum. The pressure was
monitored by a gauge needle through the septum, and the
temperature was monitored by an infrared probe at the bottom
of the glass vessel. Chromatography solvents were HPLC grade
and were used without further purification. Thin layer chroma-
tography (TLC) analysis was performed using Merck silica gel
60 F-254 thin layer plates. Flash column chromatography was
carried out using columns prepacked with 40-63 μm silica.
NMR spectra were recorded on a Bruker Advance 500 MHz
spectrometer, and samples were referenced to the appropriate
internal nondeuterated solvent peak. In the case where a 1:1
mixture of MeOD and CDCl3 was used, the samples were
referenced to MeOD. The data are given as follows: chemical
shift (δ) in ppm, multiplicity (where applicable), coupling con-
stants (J ) in Hz (where applicable), and integration (where
applicable). LC-MS analyses were performed on a Micromass
LCT/Waters Alliance 2795 separations module HPLC system
with a Merck Chromolith SpeedROD RP-18e 50 mm4.6 mm
column at a temperature of 22 C. The following solvent system,
at a flow rate of 2 mL/min, was used: solvent A, methanol;
solvent B, 0.1% formic acid in water. Gradient elution was as
follows: 1:9 (A/B) to 9:1 (A/B) over 2.25min, 9:1 (A/B) for 0.75min
and then reversion back to 1:9 (A/B) over 0.3 min, 1:9 (A/B) for
0.2 min Detection was with a Waters 2487 dual λ absorbance
detector (detecting at 254 nm), and ionization was electrospray
(ESI). Some LC-MS and all HRMS analyses were performed
on aAgilent 1200 seriesHPLC systemwith aMerckChromolith
SpeedRODRP-18e 50mm4.6mm column at a temperature of
22 C. The following solvent system, at a flow rate of 2 mL/min,
was used: solvent A, methanol; solvent B, 0.1% formic acid in
water. Gradient elution was as follows: 1:9 (A/B) to 9:1 (A/B)
over 2.5 min, 9:1 (A/B) for 1 min and then reversion back to 1:9
(A/B) over 0.3 min, 1:9 (A/B) for 0.2 min. This was connected to
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a Agilent 6200 time of flight (ToF) mass spectrometer (simul-
taneous ESI and APCI or ESI only) with detection at 254 nm.
The following reference masses were used for HRMS analysis:
caffeine [MþH]þ=195.087652, reserpine [MþH]þ=609.280657,
and (1H,1H,3H-tetrafluoropentoxy)phosphazene [M þ H]þ=
922.009 798. The purity of final compounds was determined
by HPLC as described above and are g95% unless specified
otherwise.
Ethyl 1-benzyl-5-(trifluoromethylsulfonyloxy)-1,2,3,6-tetra-
hydropyridine-4-carboxylate (44). Sodium hydride 60% (0.37 g,
9.36 mmol) was washed under N2 with dry hexane (5 mL). Ether
(5 mL) was added, and the suspension was cooled to 0 C. Ethyl
1-benzyl-3-oxo-4-piperidinecarboxylate (1.22 g, 4.68 mmol) in
ether (23 mL) was then added, and the resulting slurry was stirred
at ambient temperature for 1 h. After the mixture was recooled to
0 C, trifluoromethanesulfonic anhydride (1.19 mL, 7.02 mmol)
was added dropwise. The mixture was stirred for 30 min and then
warmed to ambient temperature and stirred for 1.5 h before being
cooled to 0 C and water (75 mL) was added dropwise. The
mixturewas extractedwithCH2Cl2 (375mL), and the combined
organic layers were dried over MgSO4, concentrated, and dried in
vacuo.Thecrudematerialwaspurifiedby flashcolumnchromatog-
raphy (0-30% EtOAc in hexane) to give triflate 44 (1.82 g, 99%)
as a pale orange oil: 1H NMR (500 MHz, CDCl3) δ 7.50-7.14
(m, 4H), 4.29 (q, J=7.2 Hz, 1H), 3.64 (s, 2H), 3.18 (t, J=2.6 Hz,
1H), 2.65 (t, J=8.5 Hz, 1H), 2.61-2.55 (m, 1H), 1.32 (t, J=7.2
Hz, 2H); 13CNMR(126MHz,CDCl3) δ163.7, 148.8, 137.0, 128.8,
128.5, 127.6, 121.4, 118.3 (q, J=319.9 Hz), 61.7, 61.2, 53.2, 48.2,
26.0, 14.0; LC-MSm/z 394 [MþH]þ; HRMS (ESI)m/z calcd for
C16H19F3NO5S [M þ H]þ 394.093 05, found 394.09307.
General Procedure A: Ethyl 1-benzyl-5-methyl-1,2,3,6-tetra-
hydropyridine-4-carboxylate (45a). To a stirred solution of triflate
44 (1.13g, 2.88mmol) and tetrakis(triphenylphosphine)palladium-
(0) (0.33 g, 0.29 mmol) in THF (72 mL) at 0 C was added di-
methylzinc (1 M in toluene, 4.9 mL, 4.9 mmol). The mixture was
allowed to warm to ambient temperature and stirred for 24 h.
Water (100 mL) and brine (100 mL) were added, and the mixture
was extracted with EtOAc (2100 mL) and CH2Cl2 (250 mL).
The organic layers were combined, dried over MgSO4, and con-
centrated in vacuo. The crude material was purified flash column
chromatography (0-45% EtOAc in hexane) to give N-benzyl-
methyltetrahydropyridine 45a (0.67 g, 90%): 1HNMR (500MHz,
CDCl3) δ 7.37-7.29 (m, 4H), 7.29-7.23 (m, 1H), 4.18 (q, J=7.1
Hz, 2H), 3.58 (s, 2H), 2.99 (t, J=1.9 Hz, 2H), 2.55 (t, J=5.8 Hz,
2H), 2.50-2.31 (m, 2H), 1.98 (s, 3H), 1.27 (t, J=7.1Hz, 3H); 13C
NMR(126MHz,CDCl3) δ 167.7, 144.7, 137.9, 129.0, 128.2, 127.1,
122.4, 62.2, 59.8, 59.3, 49.4, 26.8, 19.2, 14.3; LC-MSm/z 260 [Mþ
H]þ;HRMS(ESI)m/z calcd forC16H22NO2 [MþH]þ 260.16451,
found 260.16527.
Compound 45b was synthesized in a similar manner, and the
data are available in the Supporting Information.
General Procedure B: Ethyl 5-methyl-1,2,3,6-tetrahydropyr-
idine-4-carboxylate. To a stirred solution of N-benzylmethylte-
trahydropyridine 45a in dichloroethane (40 mL) under N2 at
0 C was added dropwise R-chloroethyl chloroformate (0.29 mL,
2.71 mmol). The mixture was then heated at reflux for 1 h. The
solvent was concentrated in situ, and dry MeOH (20 mL) was
added. This mixture was heated at reflux for 2 h and then
concentrated in vacuo. This material was partitioned between
CH2Cl2 (50mL) and 1M aqueousNaOH (50mL). The aqueous
layer was separated and extracted with CH2Cl2 (250mL). The
organic layers were combined, dried over MgSO4, concentrated
in vacuo, and used crude in the next step.
General Procedure C: (()-(3R,4R)-Ethyl 3-methylpiperidine-
4-carboxylate (46a). The crude debenzylated product (0.53 g,
2.58 mmol) was dissolved in AcOH (50 mL), and platinum
dioxide (0.06 g, 0.26 mmol) was added. The mixture was
hydrogenated in a Parr apparatus at 50 psi and 40 C for 21 h.
It was then filtered through Celite and washed with EtOAc. The
filtrate was evaporated and then partitioned between 1 M aqueous
KOH (50 mL) and CH2Cl2/MeOH (9:1, 50 mL). The aque-
ous layer was extracted with CH2Cl2/MeOH (9:1, 2 50 mL).
The combined organic extracts were combined, dried over
MgSO4, and concentrated in vacuo. The crude material was
purified by flash column chromatography (0-10%, 1Mmetha-
nolic ammonia in CH2Cl2) to give 3-methylpiperidine 46a as
a clear oil which became a white crystalline solid on standing
(0.30 g, 68% (two steps)): 1H NMR (500 MHz, CDCl3) δ
4.15-4.02 (m, 2H), 3.05 (dt, J=12.4, 4.0 Hz, 1H), 2.84 (dd, J=
12.5, 4.0 Hz, 1H), 2.78 (dd, J=12.5, 3.5 Hz, 1H), 2.60 (ddd, J=
12.4, 10.1, 4.0 Hz, 1H), 2.55 (dt, J=10.1, 4.0 Hz, 1H), 2.41 (br s,
1H), 2.09 (m, 1H), 1.76 (dtd, J=14.0, 10.1, 4.0 Hz, 1H), 1.61
(dq, J=14.0, 4.0 Hz, 1H), 1.21 (t, J=7.1 Hz, 3H), 0.92 (d, J=
7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.2, 60.0, 51.5,
44.8, 44.4, 31.0, 24.3, 14.2, 13.6; LC-MS m/z 172 [M þ H]þ;
HRMS (ESI) m/z calcd for C9H17NO2 [M þ H]þ 172.133 21,
found 172.133 39.
Compounds 46b-dwere synthesized in a similarmanner, and
the data are available in the Supporting Information.
General Procedure D: (()-(3R,4R)-Ethyl 1-(3-amino-6-bromo-
pyrazin-2-yl)-3-methylpiperidine-4-carboxylate (47a). 2-Amino-
5-bromo-3-chloropyrazine (41) (0.44 g, 2.109 mmol), 3-methyl-
piperidine 46a (0.301 g, 1.76 mmol), and DIPEA (0.46 mL, 2.64
mmol) were dissolved in NMP (4.4 mL) in a microwave vial
under N2. The mixture was then heated at 140 C for 1 h 20 min
in a microwave. Then 1 M KOH (50 mL) was added and the
mixture was extracted with CH2Cl2 (3 50 mL). The organic
layers were combined, dried over MgSO4, and separated from
NMP using a Biotage SCX-2 column (5 g) and eluting with
0-10%MeOH in CH2Cl2 and then 50% methanolic ammonia
in CH2Cl2. The crude material was purified by flash column
chromatography (0-30% EtOAc in hexane) to give bromopyr-
azinyl-3-methylpiperidine 47a (0.42 g, 70%): 1H NMR (500
MHz, CDCl3) δ 7.70 (s, 1H), 4.64 (br s, 2H), 4.25-4.03 (m, 2H),
3.49 (dtd, J=12.5, 4.1, 1.7 Hz, 1H), 3.39 (ddd, J=12.5, 3.9, 1.7
Hz, 1H), 2.91 (dd, J=12.5, 3.1Hz, 1H), 2.82 (ddd, J=12.5, 11.2,
3.1Hz, 1H), 2.62 (dt, J=11.0, 4.4Hz, 1H), 2.42-2.35 (m, 1H), 2.01
(dtd, J=17.9, 11.2, 4.1 Hz, 1H), 1.89-1.80 (m, 1H), 1.26 (t, J=
7.1 Hz, 3H), 1.07 (d, J= 7.0 Hz, 3H); 13C NMR (126 MHz,
CDCl3) δ 173.7, 147.2, 146.9, 136.6, 124.3, 60.3, 53.8, 47.7, 44.2,
30.9, 23.0, 14.2, 13.6; LC-MS m/z 343, 345 [M þ H]þ; HRMS
(ESI) m/z calcd for C13H20
79BrN4O2 [M þ H]þ 343.076 41,
found 343.076 96.
Compounds 47b-dwere synthesized in a similarmanner, and
the data are available in the Supporting Information.
General Procedure E: (()-(3R,4R)-Ethyl 1-(3-amino-6-(3,4,5-
trimethoxyphenyl)pyrazin-2-yl)-3-methylpiperidine-4-carboxylate
(48a).Bromopyrazinyl-3-methylpiperidine47a (0.09g, 0.25mmol),
trimethoxyphenylboronic acid (0.08 g, 0.38 mmol), Pd(dppf)-
Cl2 3CH2Cl2 (0.02 g, 0.03 mmol), and aqueous Na2CO3 solu-
tion (2 M, 0.25 mL, 0.50 mmol) were dissolved in DME (0.5 mL)
in a microwave vial under argon and heated in a microwave at
105 C for 2 h. Water (10 mL) was added, and the mixture was
extracted with CH2Cl2 (3  10 mL). The organic layers were
combined, dried over MgSO4, and concentrated in vacuo. The
crude material was purified by flash column chromatography
(0-80% EtOAc in hexane) to give trimethoxyphenylpyrazine
48a (0.10 g, 96%): 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H),
7.13 (s, 2H), 4.70 (br s, 2H), 4.23-4.14 (m, 2H), 3.93 (s, 6H), 3.87
(s, 3H), 3.63-3.57 (m, 1H), 3.48 (ddd, J=12.4, 3.8, 1.3 Hz, 1H),
3.01 (dd, J=12.5, 3.0 Hz, 1H), 2.94 (td, J=12.5, 2.9 Hz, 1H),
2.67 (dt, J=11.0, 4.4 Hz, 1H), 2.50-2.39 (m, 1H), 2.17-2.03
(m, 1H), 1.95-1.86 (m, 1H), 1.28 (t, J=7.1Hz, 3H), 1.13 (d, J=
7.0Hz, 3H); 13CNMR (126MHz, CDCl3) δ 174.0, 153.5, 147.2,
146.4, 140.3, 138.3, 133.2, 132.0, 103.0, 60.9, 60.3, 56.2, 54.1,
47.8, 44.5, 31.1, 23.3, 14.3, 13.8; LC-MS m/z 431 [M þ H]þ;
HRMS (ESI) m/z calcd for C22H31N4O5 [M þ H]þ 431.2289,
found 431.2288.
Compounds 48b-dwere synthesized in a similarmanner, and
the data are available in the Supporting Information.
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(þ)-(3S,4S)-Ethyl 1-(3-amino-6-(3,4,5-trimethoxyphenyl)pyrazin-
2-yl)-3-methylpiperidine-4-carboxylate. The enantiomers were
separated by semipreparative chiral HPLC (Chiralpak IA column
(250 mm 10 mm), detection at λ=254 nm, isocratic elution
100% IPA, flow rate of 2.0 mL/min, run time of 60 min) t(þ)=
27.5min; analytical HPLC (IAChiralpak column, detection λ=
254 nm, injection volume of 5 μL, isocratic elution 100% IPA,
flow rate of 0.25 mL/min, run time of 65 min) t(þ)= 42.5 min,
97% ee; [R]20D þ10 (c 0.35, MeOH).
(-)-(3R,4R)-Ethyl 1-(3-amino-6-(3,4,5-trimethoxyphenyl)-
pyrazin-2-yl)-3-methylpiperidine-4-carboxylate. Continued semi-
preparative chiral HPLC (as above) t(-) = 32.7 min; analytical
HPLC (as above) t(-) = 49.5 min, 93% ee; [R]20D -10 (c 0.36,
MeOH).
General Procedure F: (()-(3R,4R)-1-(3-Amino-6-(3,4,5-tri-
methoxyphenyl)pyrazin-2-yl)-3-methylpiperidine-4-carboxylic Acid
(19). ((Trimethoxyphenyl)pyrazinyl)methylpiperidine ester 48a
(19 mg, 0.044 mmol) was dissolved in methanol (3.7 mL), and
aqueous NaOH solution (1 M, 3.7 mmol, 3.7 mL) was added.
The mixture was then heated at 60 C for 2 h. After cooling to
ambient temperature, the solution wasmade pH 5 by careful addi-
tion of aqueous 1MHCl (and aqueous 1MNaOH if necessary)
which, upon standing, produced a precipitate. This was filtered,
washed with a cold mixture of water/MeOH (3:2), and dried in
vacuo to give methylpiperidine carboxylic acid 19 (8 mg, 45%):
1HNMR (500MHz, CDCl3) δ 8.00 (s, 1H), 7.12 (s, 2H), 5.34 (br
s, 2H), 3.94 (s, 6H), 3.88 (s, 3H), 3.66-3.60 (m, 1H), 3.52 (dd, J=
12.5, 2.9 Hz, 1H), 3.04 (dd, J=12.5, 2.9 Hz, 1H), 3.02-2.96 (m,
1H), 2.76 (dt, J=10.9, 4.3 Hz, 1H), 2.55-2.48 (m, 1H), 2.17-
2.07 (m, 1H), 1.99-1.92 (m, 1H), 1.22 (d, J=6.8 Hz, 3H); 13C
NMR (126 MHz, CDCl3) δ 178.3, 153.6, 147.0, 147.0, 140.1,
138.5, 132.8, 129.9, 103.0, 60.9, 56.3, 54.1, 47.8, 44.3, 31.1, 23.2,
13.8; LC-MS m/z 403 [M þ H]þ; HRMS (ESI) m/z calcd for
C20H27N4O5 [M þ H]þ 403.197 60, found 403.197 50.
Compounds 23 and 25 were synthesized in a similar manner,
and the data are available in the Supporting Information.
General Procedure G: (-)-(3S,4S)-1-(3-Amino-6-(3,4,5-tri-
methoxyphenyl)pyrazin-2-yl)-3-methylpiperidine-4-carboxylic Acid
(20). Preparation was from (þ)-((trimethoxyphenyl)pyrazinyl
methylpiperidine ester (4 mg, 0.010 mmol) according to general
procedure F but with the following workup procedure: the
solution was made pH 5 by careful addition of aqueous 1 M
HCl (and aqueous 1 M NaOH if necessary) and was extracted
with CH2Cl2/MeOH (9:1, 3  5 mL). The combined organic
layers were dried overMgSO4, concentrated, and dried in vacuo
to give (-)-ethylpiperidine carboxylic acid 20 (4mg, 99%, purity
94%): [R]20D -24 (c 0.36, MeOH); LC-MS m/z 403 [M þH]þ;
HRMS (ESI) m/z calcd for C20H27N4O5 [M þ H]þ 403.1976,
found 403.1983.
(þ)-(3R,4R)-1-(3-Amino-6-(3,4,5-trimethoxyphenyl)pyrazin-
2-yl)-3-methylpiperidine-4-carboxylic Acid (21). Preparation
from (-)-((trimethoxyphenyl)pyrazinyl)methylpiperidine ester
(4 mg, 0.010 mmol) according to general procedure G gave (þ)-
ethylpiperidine carboxylic acid (4 mg, 99%): [R]20Dþ33 (c 0.36,
MeOH); LC-MSm/z 403 [MþH]þ; HRMS (ESI)m/z calcd for
C20H27N4O5 [M þ H]þ 403.1976, found 403.1990.
Methyl 2,3-dimethylisonicotinate (54d). 4,5-Dimethyloxazole37
(53) (3.12 g, 32.1 mmol), methyl acrylate (5.8 mL, 64.3 mmol),
and hydroquinone (0.03 g, 0.28 mmol) were dissolved in benzene
(6.2 mL) and heated at reflux for 18 h. The solvent was concentra-
ted in vacuo, and the crude material was purified by flash column
chromatography (0-50% EtOAc in hexane) to give methyl 2,3-
dimethylisonicotinate (54d) (2.36 g, 44%): 1H NMR (500 MHz,
CDCl3) δ 8.39 (d, J=5.1 Hz, 1H), 7.39 (d, J=5.1 Hz, 1H), 3.91
(s, 3H), 2.58 (s, 3H), 2.45 (s, 3H); 13C NMR (126 MHz, CDCl3)
δ 167.5, 159.1, 146.2, 137.9, 130.8, 120.7, 52.4, 23.3, 15.9; LC-MS
m/z166 [MþH]þ;HRMS(ESI)m/zcalcd forC9H12NO2 [MþH]þ
166.0863, found 166.0868.
General Procedure H: (()-(2R,3R,4R)-Methyl 2,3-dimethyl-
piperidine-4-carboxylate (55d). To a solution of dimethylisoni-
cotinate 54d (0.59 g, 3.57mmol) in acetic acid (40mL)was added
PtO2 (0.07 g, 0.29mmol). Themixture was then hydrogenated in
a Parr apparatus at 50 bar and 50 C for 18 h. It was then filtered
through Celite and concentrated in vacuo. Aqueous 1MNaOH
(50mL) was added, and themixture was extracted with CH2Cl2/
MeOH (9:1, 3  50 mL). The organic layers were combined,
dried over MgSO4, and concentrated in vacuo. The crude mate-
rial was purified by flash column chromatography (0-10%, 1M
methanolic ammonia in CH2Cl2) to give dimethylpiperidine 55d
(0.47 g, 77%): 1H NMR (500 MHz, CDCl3) δ 3.68 (s, 3H), 3.15
(ddd, J=12.7, 4.4, 2.1 Hz, 1H), 2.88 (qd, J=6.6, 2.9 Hz, 1H),
2.65 (td, J=12.7, 3.2 Hz, 1H), 2.57 (dt, J=12.7, 4.0 Hz, 1H),
2.52 (s, 1H), 2.16-2.09 (m, 1H), 1.77 (qd, J=12.7, 4.4 Hz, 1H),
1.67-1.60 (m, 1H), 1.08 (d, J=6.6 Hz, 1H), 0.83 (d, J=7.0 Hz,
3H); 13CNMR(126MHz,CDCl3) δ 174.6, 55.0, 51.2, 46.7, 46.1,
34.9, 21.9, 19.7, 6.8; LC-MSm/z 172 [MþH]þ;HRMS (ESI)m/z
calcd for C9H18NO2 [M þ H]þ 172.133 21, found 172.132 99.
Compounds 54a-cwere synthesized in a similarmanner, and
the data are available in the Supporting Information.
General Procedure I: (()-(2R,3R,4R)-Methyl 1-(6-chloro-
4-(4-methoxybenzyl)-3-oxo-3,4-dihydropyrazin-2-yl)-2,3-dimethyl-
piperidine-4-carboxylate (57d). 3,5-Dichloro-1-(4-methoxyben-
zyl)pyrazin-2(1H)-one (56) (0.47 g, 2.73 mmol) was dissolved
in NMP (6.5 mL). DIPEA (0.54 mL, 3.12 mmol) and
2,3-dimethylpiperidine 55d (0.47 g, 2.73 mmol) were added, and
the mixture was heated in a microwave at 140 C for 2 h. The
DIPEAwas then removedby concentration invacuo, and the crude
material, including NMP solvent, was purified by flash column
chromatography (0-20% EtOAc in hexane) to give dimethylpi-
peridinylpyrazinone 57d (0.60 g, 55%): 1H NMR (500 MHz,
CDCl3) δ 7.25-7.21 (m, 2H), 6.89-6.85 (m, 2H), 6.57 (s, 1H),
4.95-4.89 (m, 1H), 4.92 (d, J=14.1Hz, 1H), 4.85 (d, J=14.1Hz,
1H), 4.59 (dt, J=13.8, 3.3 Hz, 1H), 3.78 (s, 3H), 3.69 (s, 3H), 3.53
(ddd, J=14.0, 12.5, 3.3 Hz, 1H), 2.64 (td, J=5.5, 3.3 Hz, 1H),
2.29-2.21 (m, 1H), 2.08 (dq, J=13.8, 3.3 Hz, 1H), 1.88-1.78 (m,
1H), 1.15 (d, J=7.0 Hz, 3H), 1.11 (d, J=7.4 Hz, 3H); 13C NMR
(126MHz,CDCl3) δ175.4, 159.6, 151.3, 150.8, 129.8, 127.3, 125.7,
114.3, 114.0, 55.2, 53.3, 51.5, 51.2, 41.0, 37.9, 36.3, 27.2, 16.6,
11.8; LC-MS m/z 420 [M þ H]þ; HRMS (ESI) m/z calcd for
C21H27ClN3O4 [M þ H]þ 420.168 46, found 420.169 63.
Compounds 57a-cwere synthesized in a similarmanner, and
the data are available in the Supporting Information.
General Procedure J: (()-(2R,3R,4R)-Methyl 1-(4-(4-meth-
oxybenzyl)-3-oxo-6-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrazin-
2-yl)-2,3-dimethylpiperidine-4-carboxylate. Dimethylpiperidinyl-
pyrazinone 57d (0.54 g, 1.29 mmol), (3,4,5-trimethoxyphenyl)-
tributyltin40 (1.18 g, 2.57mmol), cesium fluoride (0.65 g, 4.24mmol),
Pd2(dba)3 (18mg, 19μmol), SPhos (32mg, 0.077mmol), and aceto-
nitrile (19mL)were combinedandheated inamicrowave at 160 C
for 80 min. CH2Cl2 (20 mL) was added, and the mixture was
filtered. The filtrate was concentrated in vacuo and purified by
flash column chromatography (0-20%EtOAc in hexane) to give
trimethoxyphenylpyrazinone (0.48 g, 68%): 1HNMR(500MHz,
CDCl3) δ 7.30-7.26 (m, 2H), 7.01 (s, 1H), 6.94 (s, 2H), 6.88-6.84
(m, 2H), 5.08 (d, J=14.3 Hz, 1H), 4.99 (d, J=14.3 Hz, 1H),
4.89-4.83 (m, 1H), 4.54-4.47 (m, 1H), 3.88 (s, 6H), 3.84 (s, 3H),
3.77 (s, 3H), 3.70 (s, 3H), 3.66-3.59 (m, 1H), 2.69-2.64 (m, 1H),
2.39-2.31 (m, 1H), 2.11 (dq, J=13.6, 3.2 Hz, 1H), 1.90 (ddt, J=
13.6, 11.9, 4.9 Hz, 1H), 1.22 (d, J=7.0 Hz, 1H), 1.13 (d, J=7.4
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 175.5, 159.4, 153.3,
151.6, 151.5, 137.9, 132.6, 130.8, 129.4, 127.8, 114.5, 114.2, 102.4,
60.8, 56.1, 55.2, 53.5, 51.8, 51.2, 41.5, 38.5, 36.2, 27.0, 16.4, 11.9;
LC-MS m/z 552 [M þ H]þ; HRMS (ESI) m/z calcd for
C30H38N3O7 [M þ H]þ 552.270 43, found 552.272 10.
General Procedure K: (()-(2R,3R,4R)-Methyl 2,3-dimethyl-
1-(3-oxo-6-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrazin-2-yl)-
piperidine-4-carboxylate (58d). Trimethoxyphenylpyrazinone
(0.48 g, 0.87 mmol) was dissolved in a mixture of trifluoroa-
cetic acid and CH2Cl2 (1:1, 33 mL). Trifluoromethanesulfonic
acid (0.27 mL, 3.05 mmol) was then added and the mixture
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stirred at ambient temperature for 17 h. It was then concen-
trated, and saturated NaHCO3 solution (50 mL) was added.
The mixture was extracted with CH2Cl2 (3  50 mL), and the
organic layers were combined, dried over MgSO4, and concen-
trated in vacuo. The crude material was purified by flash column
chromatography (0-70% EtOAc in CH2Cl2) to give deprotected
pyrazinone 58d (0.21 g, 57%): 1H NMR (500 MHz, CDCl3) δ
12.09 (s, 1H), 7.14 (s, 1H), 7.03 (s, 2H), 4.87-4.79 (m, 1H), 4.53
(dt, J=13.6, 3.5 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 3H), 3.72 (s, 3H),
3.71-3.63 (m, 1H), 2.72-2.66 (m, 1H), 2.43-2.35 (m, 1H), 2.14
(dq, J=13.5, 3.5Hz, 1H), 1.96-1.84 (m, 1H), 1.24 (d, J=7.0Hz,
3H), 1.16 (d, J=7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ
175.4, 153.3 (2C), 151.2, 137.7, 132.4, 132.1, 111.4, 102.2, 60.8, 56.0,
53.2, 51.2, 41.5, 38.5, 36.0, 26.9, 16.3, 11.9; LC-MS m/z 432
[M þH]þ; HRMS (ESI) m/z calcd for C22H30N3O6 [M þ H]þ
432.212 91, found 432.213 10.
Compounds 58a-cwere synthesized in a similar manner, and
the data are available in the Supporting Information.
General Procedure L: (()-(2R,3R,4R)-Methyl 2,3-dimethyl-
1-(3-(trifluoromethylsulfonyloxy)-6-(3,4,5-trimethoxyphenyl)-
pyrazin-2-yl)piperidine-4-carboxylate. Deprotected pyrazinone
58d (0.10g, 0.23mmol)wasdissolved inCHCl3 (7.5mL) andcooled
to 0 C.DIPEA (0.06mL, 0.36mmol)was added followedby tri-
fluoromethanesulfonicanhydride (0.06mL,0.36mmol).Themixture
was warmed to ambient temperature and stirred for 1 h. The
solvent was then removed by concentration in vacuo and the
crude material was purified by flash column chromatography
(0-40% EtOAc in hexane) to give pyrazine triflate (0.10 g,
82%): 1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.20 (s, 2H),
3.94 (s, 6H), 3.90 (s, 3H), 3.90-3.85 (m, 1H), 3.72 (s, 3H), 3.58
(ddd, J=12.6, 6.6, 3.8 Hz, 1H), 3.22 (ddd, J=12.6, 8.7, 3.6 Hz,
1H), 2.69 (dt, J=8.8, 4.5Hz, 1H), 2.41-2.30 (m, 1H), 2.24-2.14
(m, 1H), 1.91-1.80 (m, 1H), 1.19 (d, J=6.6Hz, 3H), 1.08 (d, J=
7.1Hz, 3H); 13CNMR (126MHz, CDCl3) δ 174.7, 153.7, 150.4,
149.7, 144.1, 140.2, 130.6, 130.1, 118.4 (q, J=320.6 Hz), 104.4,
60.9, 56.2, 56.0, 51.5, 47.1, 44.2, 36.4, 24.0, 15.1, 11.9; LC-MS
m/z 564 [MþH]þ; HRMS (ESI)m/z calcd for C23H29F3N3O8S
[M þ H]þ 564.162 20, found 564.163 42.
General Procedure M: (()-(2R,3R,4R)-Methyl 1-(3-(4-meth-
oxybenzylamino)-6-(3,4,5-trimethoxyphenyl)pyrazin-2-yl)-2,3-
dimethylpiperidine-4-carboxylate. Pyrazine triflate (0.04 g, 0.06
mmol), 4-methoxybenzylamine (0.02 mL, 0.16 mmol), and potas-
sium phosphate (0.02 g, 0.08 mmol) were dissolved in MeCN
(1.6 mL). Palladium(II) acetate (1.6 mg, 7 μmol) and BINAP
(7 mg, 0.012 mmol) were added. Then the mixture was heated in
a microwave at 110 C for 1 h. CH2Cl2 (10 mL) was added, and
the mixture was filtered through cotton wool and concentra-
ted in vacuo. The crude material was purified by flash column
chromatography (0-30%EtOAc in hexane) to give 4-methoxy-
benzylaminopyrazine (0.02 g, 43%): 1HNMR (500MHz, CDCl3)
δ 8.24 (s, 1H), 7.29-7.24 (m, 2H), 7.10 (s, 2H), 6.91-6.86 (m,
2H), 5.87 (s, 1H), 4.63 (dd, J=14.4, 5.3 Hz, 1H), 4.59 (dd, J=
14.4, 5.4Hz, 1H), 3.93 (s, 6H), 3.87 (s, 3H), 3.81 (s, 3H), 3.71 (s, 3H),
3.48 (qd, J=6.3, 2.8Hz, 1H), 3.15-3.06 (m, 1H), 2.78-2.67 (m,
2H), 2.34-2.25 (m, 1H), 1.99 (qd, J=13.0, 4.3 Hz, 1H), 1.80
(dd, J= 13.8, 2.8 Hz, 1H), 0.95 (d, J= 6.3 Hz, 3H), 0.92 (d,
J=6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.5, 158.9,
153.6, 149.9, 145.7, 138.4, 138.1, 134.5, 133.3, 131.3, 128.5,
114.1, 102.7, 100.0, 60.9, 57.9, 56.2, 55.3, 51.8, 51.6, 46.5,
44.6, 36.3, 22.6, 17.7, 8.5; LC-MS m/z 551 [M þ H]þ; HRMS
(ESI) m/z calcd for C30H39N4O6 [M þ H]þ 551.286 41, found
551.286 84.
General Procedure N: (()-(2R,3R,4R)-Methyl 1-(3-amino-
6-(3,4,5-trimethoxyphenyl)pyrazin-2-yl)-2,3-dimethylpiperidine-
4-carboxylate. 4-Methoxybenzylaminopyrazine (18 mg, 0.033
mmol) was dissolved in a mixture of trifluoroacetic acid and
CH2Cl2 (1:1, 3 mL), and trifluoromethanesulfonic acid (10 μL,
0.13 mmol) was added. The mixture was stirred at ambient
temperature for 2 h. It was then concentrated, and saturated
NaHCO3 solution (5mL) was added. Themixture was extracted
withCH2Cl2 (35mL), the organic layers were combined, dried
overMgSO4, and concentrated in vacuo. The crudematerial was
purified by flash column chromatography (0-50% EtOAc in
CH2Cl2) to give aminopyrazinylpiperidine ester (13 mg, 92%):
1HNMR (500MHz, CDCl3) δ 8.16 (s, 1H), 7.10 (s, 2H), 5.10 (s,
2H), 3.94 (s, 6H), 3.88 (s, 3H), 3.73 (s, 3H), 3.51 (qd, J=6.2, 2.8
Hz, 1H), 3.23-3.16 (m, 1H), 2.77-2.64 (m, 2H), 2.36-2.28 (m,
1H), 2.05 (qd, J=13.0, 4.3 Hz, 1H), 1.87-1.78 (m, 1H), 1.00 (d,
J=2.5 Hz, 3H), 0.98 (d, J=3.1 Hz, 3H); 13C NMR (126MHz,
CDCl3) δ174.6, 153.6, 150.1, 145.7, 140.5, 138.4, 133.9, 132.9, 102.9,
60.9, 57.7, 56.2, 51.6, 51.5, 46.5, 36.3, 22.6, 17.7, 8.6; LC-MS
m/z 431 [M þ H]þ; HRMS (ESI) m/z calcd for C22H31N4O5
[M þ H]þ 431.228 90, found 431.230 09.
(-)-(2R,3R,4R)-Methyl 1-(3-amino-6-(3,4,5-trimethoxyphenyl)-
pyrazin-2-yl)-2,3-dimethylpiperidine-4-carboxylate. The enantio-
mers were separated by semipreparative chiral HPLC (Chiralpak
IA column (250 mm10 mm), detection at λ=254 nm, isocratic
elution 5% IPA in MeCN, flow rate of 1.2 mL/min, run time of
30 min) t(-)=15.0 min; analytical HPLC (IA Chiralpak column,
detection λ=254 nm, injection volume of 5 μL, isocratic elution
5% IPA in MeCN, flow rate of 0.25 mL/min, run time of 30 min)
t(-)=20.8 min, 98% ee; [R]20D -65 (c 0.36, MeOH).
(þ)-(2S,3S,4S)-Methyl 1-(3-amino-6-(3,4,5-trimethoxyphenyl)-
pyrazin-2-yl)-2,3-dimethylpiperidine-4-carboxylate.Continued semi-
preparative chiral HPLC (as above) t(þ) = 16.7 min; analytical
HPLC (as above) t(þ) = 23.2 min, 87% ee; [R]20D þ35 (c 0.36,
MeOH)
(-)-(2R,3R,4R)-1-(3-Amino-6-(3,4,5-trimethoxyphenyl)pyrazin-
2-yl)-2,3-dimethylpiperidine-4-carboxylic Acid (31). Preparation
from (-)-aminopyrazine ester (13mg, 0.030mmol) according to
general procedure F gave (-)-dimethylpiperidine carboxylic
acid 31 (9 mg, 72%): [R]20D -57 (c 0.34, MeOH). LC-MS m/z
417 [M þ H]þ; HRMS (ESI) m/z calcd for C21H29N4O5 [M þ
H]þ 417.213 25, found 417.211 80. NMR characterization of the
racemate: 1H NMR (500 MHz, CDCl3) δ 8.09 (s, 1H), 7.10 (d,
J=5.1 Hz, 2H), 5.73 (br s, 2H), 3.95 (s, 6H), 3.89 (s, 3H), 3.55
(qd, J=6.3, 2.8 Hz, 1H), 3.28-3.20 (m, 1H), 2.80 (dt, J=12.5,
3.9 Hz, 1H), 2.73 (td, J=12.2, 2.5 Hz, 1H), 2.44-2.37 (m, 1H),
2.12-2.01 (m, 1H), 1.92-1.84 (m, 1H), 1.09 (d, J=6.9 Hz, 3H),
1.03 (d, J=6.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 178.8,
153.7, 150.0, 146.5, 140.1, 138.5, 132.5, 131.9, 102.9, 60.9, 57.9,
56.3, 51.5, 46.5, 36.3, 22.5, 17.7, 8.6.
(þ)-(2S,3S,4S)-1-(3-Amino-6-(3,4,5-trimethoxyphenyl)pyrazin-
2-yl)-2,3-dimethylpiperidine-4-carboxylic Acid (32). Preparation
from (þ)-aminopyrazine ester (11mg, 0.026mmol) according to
general procedure F gave (þ)-dimethylpiperidine carboxylic
acid 32 (7 mg, 66%): [R]20D þ56 (c 0.34, MeOH); LC-MS m/z
417 [MþH]þ; HRMS (ESI)m/z calcd forC21H29N4O5 [MþH]þ
417.213 25, found 417.213 38.
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